Tag: compliance

KING OF PRUSSIA, Pa., July 14, 2026 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ:VERX), a leading provider of enterprise compliance technology for global commerce, today announced that it will release second quarter 2026 financial results after the market close on Monday, August 3, 2026. A conference call to discuss the results will be held at 5:00 p.m. Eastern Time that same day.

NEW YORK, June 27, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of Class A ordinary shares of Sportradar Group AG (NASDAQ: SRAD) between November 7, 2024 and April 21, 2026, inclusive (the “Class Period”), of the important July 17, 2026 lead plaintiff deadline.

Mumbai, Maharashtra, June 27, 2026 (GLOBE NEWSWIRE) -- Today’s vehicle owners face rising repair costs, accident risks, theft concerns, and unpredictable weather conditions that can lead to major financial stress. HDFC ERGO highlights the need for wider vehicle protection as owners look beyond basic compliance and focus on financial preparedness.

BEDMINSTER, N.J., June 26, 2026 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (the “Company”) (NYSE American: MTNB) announced today that on June 24, 2026, it received a notice (the “Notice”) from the NYSE American LLC (the “NYSE American”) stating that the Company is not in compliance with the NYSE American continued listing standards set forth in Section 1003(a)(ii) of the NYSE American Company Guide (the “Company Guide”) requiring a company to have stockholders’ equity of at least $4.0 million if it has reported losses from continuing operations and/or net losses in three of its four most recent fiscal years. As of March 31, 2026, the Company had stockholders’ equity of $3.02 million and has had losses in the most recent five fiscal years ended December 31, 2025. As previously disclosed, the Company is also not in compliance with Section 1003(a)(iii) of the Company Guide requiring a company to have stockholders’ equity of at least $6.0 million if it has reported losses from continuing operations and/or net losses in its five most recent fiscal years. As of December 31, 2025, the Company had stockholders’ equity of $4.83 million and has had losses in the most recent five fiscal years ended December 31, 2025. Due to its non-compliance with Sections 1003(a)(ii) and 1003(a)(iii) of the Company Guide, the Company is subject to the procedures and requirements of Section 1009 of the Company Guide.

Neuphoria Therapeutics confirms it is in talks with Scancell Holdings plc about a possible combination

COPENHAGEN, Denmark, June 26, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the Company has been added to the broad-market Russell 3000^® Index, the large-cap Russell 1000^® Index, the small-to-mid-cap Russell 2500^® Index, and the Russell Midcap^® Index as a part of the 2026 Russell U.S. Indexes semi-annual reconstitution, effective at the close of U.S. equity markets on June 26, 2026.

If finalized, rule would level the playing field between American and foreign businesses